Bryan Garnier - COMPASS GROUP (CPG) COMPASS GROUP: IMS Q1 2021-22 – Good start | NEUTRAL | 1375p

Report

Bryan Garnier

Bruno de La Rochebrochard

COMPASS GROUP: IMS Q1 2021-22 – Good start | NEUTRAL | 1375p

COMPASS GROUP - NEUTRAL | 1375p
IMS Q1 2021-22 – Good start

Strong organic with four out of five segments above 2019revenues
FY guidance confirmed despite measures related to Omicron

03/02/2022 1 EN

Underlying

COMPASS GROUP

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Bruno de La Rochebrochard

Other Reports on these Companies

Bryan Garnier

Dropping coverage

From 30th October we will no longer include the following stocks in our research universe:ELISELIORISSSodexoCompass

October 30, 2023 October 30, 2023 1 EN

Liberum

LIBERUM: Morning Comment

New Energy Outlook, Compass Group, Balfour Beatty, JD Wetherspoon, THG Holdings, FirstGroup, CMO Group, Market Highlights

May 12, 2023 May 12, 2023 1 EN

Liberum

LIBERUM: Compass Group - Reaching recovery, small upgrades

Compass built on its momentum from the first quarter, with organic revenue growth of 25% in 1H23, with the trends of returning workers and first-time outsourcing continuing. As a result, it has nudged up guidance for the full year and announced an additional £750m share buyback (bringing the total to £1.5bn). We give our already top of the range estimates a marginal uplift, resulting in an increase in TP to 2150p (from 2010p). While we see less scope for future upgrades following the recovery phase, we do expect further compounding growth making Compass shares a core portfolio holding. Our TP ...

May 12, 2023 May 12, 2023 1 EN

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Yesterday, we hosted an exclusive fireside chat at our Paris HQ with ONWARD's co-founders, Dr. Grégoire Courtine and Dr. Jocelyne Bloch, accompanied by institutional investors, to learn about the professional endeavours that led them to jump from researchers to entrepreneurs, with a special deep-di

18h / 23m 18h / 23m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: joint-development progress in textiles

Yesterday, Avantium announced the successful development of a PEF-based spacer fabric in collaboration with partners Auping, Muller Textiles, Antex and Monosuisse. This breathable, cushioning 3D material marks a step forward for this partnership, ongoing since 2024, aiming to create PEF-based yarns

18h / 28m 18h / 28m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

A recent publication in Nature Communications (Groeneweg, van Geest et al. 2025) highlights the broad therapeutic applicability of Emcitate across the heterogeneity of the MCT8 deficient target group and supporting its uniform treatment eligibility across a genetically diverse patient population. I

18h / 34m 18h / 34m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

COMPASS GROUP: IMS Q1 2021-22 – Good start | NEUTRAL | 1375p

Dropping coverage

LIBERUM: Morning Comment

LIBERUM: Compass Group - Reaching recovery, small upgrades

ONWARD: from brainGPT to ARC-BCI – fireside chat with the founders

Avantium: joint-development progress in textiles

Egetis: Article highlights Emcitate's broad efficacy in MCT8 deficiency

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe